-
Posted by
Two Blokes Jul 24 -
Filed in
Stock
-
7 views
Roche Holding AG's Q2 and 1H 2025 earnings will, initially, broadly please the market despite recent pipeline and commercial setbacks. The pharmaceuticals division delivered strong revenue growth, up 10% year-over-year to $24bn in 1H25. The diagnostics division revenues remained flat at $7bn, attributed to specific market factors in China by Roche.
